Physiomics PLC Physiomics hires Head of Business Development
31 Agosto 2021 - 1:00AM
RNS Non-Regulatory
TIDMPYC
Physiomics PLC
31 August 2021
31 August 2021
Physiomics plc
("Physiomics") or ("the Company")
Physiomics hires Head of Business Development
Physiomics plc (AIM: PYC), the consultancy using mathematical
models to support the development of drug treatment regimens and
personalised medicine solutions, is pleased to announce that Hayley
Close has today joined the Company as Head of Business
Development.
Hayley holds a degree in Biomedical Science from University
College London and joins us from Fusion Antibodies plc where she
was Key Account Manager responsible for identifying and engaging
with new clients and developing existing business globally. At
Physiomics, Hayley will work directly with the CEO and senior
management team with the aim of significantly expanding both
existing and new business.
Dr Jim Millen, CEO, commented "Physiomics has reached the stage
of its growth where we believe there will be real benefit in
retaining a full-time business development executive. Hailey joins
us with a fantastic track-record and we look forward to working
with her to significantly expand Physiomics' business".
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
Hybridan LLP (broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to Editor
About Physiomics
Physiomics plc (AIM: PYC) is an oncology consultancy using
mathematical models to support the development of cancer treatment
regimens and personalised medicine solutions. The Company's Virtual
Tumour(TM) technology uses computer modelling to predict the
effects of cancer drugs and treatments to improve the success rate
of drug discovery and development projects while reducing time and
cost. The predictive capability of Physiomics' technologies have
been confirmed by over 80 projects, involving over 40 targets and
70 drugs, and has worked with clients such as Merck KGaA, Astellas,
Merck & Co and Bicycle Therapeutics.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAEALPXALSFEFA
(END) Dow Jones Newswires
August 31, 2021 02:00 ET (06:00 GMT)
Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024